← Agomab Therapeutics NV
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $406k |
$249k
-38.67%
|
$119k
-52.21%
|
— | — | $15.2m |
$25k
-99.84%
|
$0
-100.00%
|
$2.3m |
$42k
-98.18%
|
$0
-100.00%
|
|
| Net Interest Income | — | — | — | — | — | — | $25k |
$210k
+740.00%
|
$1.1m
+443.33%
|
$1.5m
+35.50%
|
$4.3m
+177.62%
|
|
| Research And Development | $9.9m | $11.1m | $9.8m | $6.5m | $9.5m | $14.5m | $19.4m | $26.3m | $39.3m | $48.9m | $49.8m | |
| Research and Development Expense | — | — | — | — | — | $6.3m | $17.0m | $18.4m | $11.3m | $5.8m | $49.8m | |
| General and administrative | — | — | — | — | — | $6.0m | $11.6m | $7.1m | $3.4m | $3.7m | $18.1m | |
| General and administrative expenses | — | — | — | — | — | — | — | ($6.1m) | ($10.1m) | ($12.8m) | $18.1m | |
| General and administrative expense | ($5.8m) | ($8.5m) | ($5.6m) | ($3.8m) | ($3.7m) | ($7.0m) | ($5.1m) | ($8.6m) | ($13.6m) | ($8.7m) | $18.1m | |
| Other Operating Expenses | — | — | — | — | — | — | ($886k) | ($886k) | ($1.0m) | ($1.9m) | — | |
| Total operating expenses | — | — | — | — | — | $12.4m | $28.5m | ($32.4m) | ($49.4m) | ($61.7m) | $65.9m | |
| Other operating income | — | — | — | — | — | — | ($10.8m) | ($31.2m) | ($48.0m) | ($59.3m) | — | |
| Other Non Operating Income Expenses | — | — | — | — | — | — | $11.9m | $19.0m | $848k | ($4.9m) | — | |
| Interest Expense | — | — | — | — | — | — | $45k | $31k | $67k | $60k | $200k | |
| Interest Income | — | — | — | — | — | — | $71k | $245k | $1.2m | $1.6m | $4.5m | |
| Net Non Operating Interest Income Expense | — | — | — | — | — | — | $25k | $210k | $1.1m | $1.5m | $4.3m | |
| Gain On Sale Of Security | — | — | — | — | — | — | ($86k) | $7k | ($231k) | $39k | $39k | |
| Other income | $3.7m | $8.6m | $13.0m | $1.5m | $995k | $2k | $25k | $1k | $173k | $1.8m | — | |
| Other Income Expense | — | — | — | — | — | — | $11.8m | $19.0m | $617k | ($4.8m) | ($5.0m) | |
| Loss before income taxes | — | — | — | — | — | $12.5m | $28.2m | $24.2m | $13.9m | $9.0m | — | |
| Pre-Tax Income | — | — | — | — | — | — | ($10.8m) | ($12.0m) | ($46.3m) | ($62.5m) | ($66.7m) | |
| Income tax (expense)/income | — | $199k | $305k | $298k | $298k | $484k | $368k | $619k | ($4k) | $1.7m | $0 | |
| Loss on disposal of Cantx, Inc. after income tax expense | ($569k) | — | — | — | — | — | — | — | — | — | — | |
| Income Tax expenses | — | — | — | — | — | $0 | ($534k) | $0 | $0 | $0 | $0 | |
| Net loss for the year | — | — | — | — | — | $12.5m | $27.6m | $24.2m | $13.9m | $9.0m | — | |
| Net Income From Continuing And Discontinued Operation | — | — | — | — | — | — | ($8.1m) | ($11.4m) | ($46.3m) | ($62.5m) | ($66.7m) | |
| Basic loss per share (in €) | ($2.82) | ($2.28) | ($12.48) | ($17.86) | ($0.17) | ($0.07) | ($0.19) | ($35.63) | ($107.09) | ($143.22) | — | |
| Diluted loss per share (in €) | ($2.82) | ($2.28) | ($12.48) | ($17.86) | ($0.17) | ($0.07) | ($0.19) | ($35.63) | ($107.09) | ($143.22) | — | |
| Weighted average number of common shares outstanding, Basic | — | — | — | — | — | — | — | 541k | 541k | 541k | — | |
| Weighted average number of common shares outstanding, Diluted | — | — | — | — | — | — | — | 541k | 541k | 541k | — | |
| Weighted average number of Ordinary Shares outstanding, basic | — | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | — | |
| Weighted average number of Ordinary Shares outstanding, diluted | — | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | — | |
| Basic Average Shares | — | — | — | — | — | — | $36.2m | $36.2m | $36.2m | — | $49.2m | |
| Diluted Average Shares | — | — | — | — | — | — | $36.2m | $36.2m | $36.2m | — | $49.2m | |
| Changes in fair value of financial liabilities | — | — | — | — | — | — | — | $19.0m | $848k | ($4.9m) | — | |
| Financial income | — | — | — | $100k | $66k | $42k | $2k | $303k | $1.3m | $1.7m | — | |
| Loss before taxes | ($12.2m) | ($10.9m) | ($6.3m) | ($10.6m) | ($12.8m) | ($8.9m) | ($25.4m) | ($12.0m) | ($46.3m) | ($62.5m) | — | |
| Loss for the year | ($12.2m) | ($10.7m) | ($6.0m) | ($10.3m) | ($12.5m) | ($8.4m) | ($25.0m) | ($11.4m) | ($46.3m) | ($62.5m) | — | |
| Impairment of intangible assets | — | — | — | — | — | — | — | $0 | $0 | ($13.4m) | — | |
| (Loss) gain on remeasurement of other financial liabilities | — | — | — | — | — | — | $0 | $0 | $1.3m | ($2.5m) | — | |
| Gain on remeasurement of promissory note | — | — | — | — | — | — | $0 | $0 | $25k | $0 | — | |
| Gain on remeasurement of contingent consideration | — | — | — | — | — | ($2.6m) | $0 | $3.4m | $119k | $7.6m | — | |
| Net exchange difference on translation of financial statements of foreign controlled entities, net of tax | ($1k) | $25k | ($251k) | ($89k) | ($4k) | $2k | $35k | $110k | ($8k) | ($23k) | — | |
| Other comprehensive income (loss), net of tax | $174k | $34k | ($251k) | ($89k) | ($4k) | $2k | $35k | $110k | ($8k) | ($23k) | — | |
| Commercialisation | — | — | — | — | $0 | $0 | ($127k) | $0 | $0 | — | — | |
| Owners of Kazia Therapeutics Limited | ($12.1m) | ($10.7m) | ($6.0m) | ($10.3m) | ($12.5m) | ($8.4m) | ($25.0m) | ($20.5m) | — | — | — | |
| Fair value losses on financial assets at fair value through profit or loss | — | — | ($1.1m) | ($1.8m) | ($168k) | $0 | $0 | — | — | — | — | |
| Loss on revaluation of contingent consideration | — | — | — | ($63k) | ($474k) | ($2.6m) | ($152k) | — | — | — | — | |
| Loss on disposal of fixed assets | ($2k) | ($16k) | ($137k) | ($1k) | — | — | — | — | — | — | — | |
| Impairment of financial assets | — | — | ($2.8m) | — | — | — | — | — | — | — | — | |
| Gain/(Loss) on the revaluation of available-for-sale financial assets, net of tax | ($3k) | $9k | — | — | — | — | — | — | — | — | — | |
| Derecognition of foreign currency reserve relating to Cantx Inc. | $178k | — | — | — | — | — | — | — | — | — | — | |
| Non-controlling interest | ($92k) | — | — | — | — | — | — | — | — | — | — | |
| Financing income, net | — | — | — | — | — | $111k | ($353k) | ($1.2m) | ($794k) | ($572k) | — | |
| Depreciation Amortization Depletion Income Statement | — | — | — | — | — | — | $23k | $99k | $311k | $219k | $219k | |
| Depreciation And Amortization In Income Statement | — | — | — | — | — | — | $23k | $99k | $311k | $219k | $219k | |
| Diluted EPS | — | — | — | — | — | — | ($0.22) | ($0.31) | ($1.28) | — | ($1.35) | |
| Diluted NI Availto Com Stockholders | — | — | — | — | — | — | ($8.1m) | ($11.4m) | ($46.3m) | ($62.5m) | ($66.7m) | |
| Normalized EBITDA | — | — | — | — | — | — | ($10.7m) | ($11.9m) | ($45.7m) | ($62.3m) | ($66.3m) | |
| Normalized Income | — | — | — | — | — | — | ($8.1m) | ($11.4m) | ($46.1m) | ($62.6m) | ($66.7m) | |
| Other Gand A | — | — | — | — | — | — | $1.6m | $2.3m | $4.6m | $3.3m | — | |
| Other Taxes | — | — | — | — | — | — | ($414k) | ($331k) | ($398k) | ($512k) | ($512k) | |
| Reconciled Depreciation | — | — | — | — | — | — | $23k | $99k | $311k | $219k | $219k | |
| Rent And Landing Fees | — | — | — | — | — | — | $122k | $178k | $137k | $211k | $211k | |
| Salaries And Wages | — | — | — | — | — | — | $2.8m | $3.5m | $5.1m | $9.1m | $9.1m | |
| Selling General And Administration | — | — | — | — | — | — | $4.5m | $6.0m | $9.8m | $12.6m | — | |
| Tax Effect Of Unusual Items | — | — | — | — | — | — | ($34k) | $350 | ($58k) | $0 | $0 | |
| Tax Provision | — | — | — | — | — | — | ($2.7m) | ($619k) | $4k | $0 | $0 | |
| Tax Rate For Calcs | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Financial expenses | — | — | — | — | — | — | — | ($86k) | ($357k) | ($133k) | — | |
| Operating Expense | — | — | — | — | — | — | $22.6m | $31.2m | $48.0m | $59.3m | $65.9m | |
| Rent Expense Supplemental | — | — | — | — | — | — | $122k | $178k | $137k | $211k | $211k | |
| Total comprehensive income/(loss) | ($12.0m) | ($10.6m) | ($6.3m) | ($10.4m) | ($12.5m) | ($8.4m) | ($25.0m) | ($20.4m) | ($26.8m) | ($20.7m) | — | |
| Total Unusual Items | — | — | — | — | — | — | ($86k) | $7k | ($231k) | $39k | $39k | |
| Total Expenses | — | — | — | — | — | — | $22.6m | $31.2m | $48.0m | $59.3m | $65.9m | |
| Total Other Finance Cost | — | — | — | — | — | — | $1k | $4k | $10k | $3k | $3k |